A study comparing the drug survival and safety of adalimumab biosimilars with Humira among new users found similar results. However, patients switching from Humira to biosimilars had a 35% higher discontinuation rate. The study included 7387 adalimumab-naive patients and 3654 switchers. All-cause drug discontinuation rates were similar between new users of biosimilars and Humira, but higher among switchers. Serious adverse events were comparable between new users of Humira and biosimilars. The study supports biosimilars as viable alternatives for new patients, but suggests closer monitoring and support for patients switching from Humira to biosimilars. Limitations include unmeasured factors influencing drug survival and unavailable reasons for discontinuation. The study was funded by various sources and disclosures were noted in the original article.
Source link
Adalimumab Biosimilars Comparable With Originator
